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Cytomegalovirus (CMV), a member of the herpesvirus family, establishes acute and chronic infections. After primary infection, CMV remains in the host in a latent state from which reactivation can occur. Infection of immunocompetent hosts is usually asymptomatic, whereas infection or virus reactivation in the immunocompromised host can cause severe and fatal disease. CMV is a serious problem for patients with organ transplants and represents the most frequent viral cause of death in patients with AIDS (6, 18) .
Studies on infection of mice with murine CMV (MCMV), a model for CMV disease, have shown that although natural killer (NK) cell functions are associated with resistance to infection with high doses of virus, survival requires the presence of T lymphocytes (33) . In our own studies concerned with the adoptive immunotherapy of the imimunocompromised infected host, we were able to identify CD8+ T lymphocytes as a major protective principle (reviewed in reference 16) . With the mouse model, the definition of major antigens (24) , the identification of antigenic peptides presented by major histocompatibility complex (MHC) class I molecules (26) , the principles of variable antigen presentation during viral replication (3) , and the construction of experimental recombinant vaccines (4, 5, 10, 32) have been carried out. Still, analysis of the protective immune mechanisms operative during acute infection failed to explain a long-established notion, namely, the production of CMV in salivary gland tissues and virus excretion even by immunocompetent hosts. Ultrastructural examinations have located the acinar glandular epithelial cells as the site of chronic infection (9) . Recently, we reported that, unlike in all other tissues tested, CD8+ T lymphocytes alone cannot clear (11) and CD4+ T lymphocytes are essential for the clearance of salivary gland * Corresponding author.
tissues, a function that does not even require the contribution of CD8+ T lymphocytes (12) .
In this study, we have characterized the CD4 T-lymphocyte subset involved. We identified the protective CD4 subset as Thl cells by the correlation between function and endogenous gamma interferon (IFN-y) activity. We report that neutralization of IFN-y abolishes the antiviral activity of CD4+ but not of CD8+ T lymphocytes. Because recombinant IFN-y (rIFN-y) cannot replace Thl cells and has limited direct antiviral activity, this cytokine probably represents only one of the essential factors required for the establishment of viral latency in the infected host.
MATERIALS AND METHODS
Mice. Female BALB/c (H-2d) and CBA/J (H-2k) mice, 7 to 9 weeks old, were obtained from our own breeding colony. Thymectomized mice were prepared by the standard procedure for adult thymectomy (12) .
Virus, virus titrations, and infection conditions. Sucrose gradient-purified mouse embryo fibroblast culture-propagated MCMV (Smith strain; code VR-194; American Type Culture Collection, Rockville, Md.) was used. MCMV in tissues was quantified by a plaque assay (27) (2) , which recognizes the murine CD4 antigen; 169.4 (rat IgG2b) (2) and 19.178 (mouse IgG2a) (8) , both specific for the murine CD8 antigen; and R4.6A2 (rat IgGl), which neutralizes murine IFN-y (30). Antibodies were partially purified from ascitic fluid or tissue culture supernatant by 50% ammonium sulfate precipitation, followed by dialysis in PBS (pH 7.6), and stored at -30°C until use. The concentration of rat IgG in the MAb stocks used in vivo was determined by a radial immunodiffusion assay with rat and mouse IgG standards (Serotec, Oxford, England). The IFN-y-neutralizing capacity of MAb R4.6A2 stocks was determined in a cell protection assay on an L929 monolayer grown in 96-well flat-bottomed plates after infection with vesicular stomatitis virus, using a standard technique described elsewhere (18) . The neutralizing capacity of the anti-IFN--y MAb stock was ca. 5 X 104 U/mg.
In vivo treatment of mice. In vivo depletion of CD4+ and CD8+ T-lymphocyte subsets was carried out as described previously (11, 12) . In thymectomized mice, long-term depletion of the CD4 and CD8 subsets was accomplished by intravenous treatment with anti-CD4 or anti-CD8 MAb, respectively, at a dose of ca. 1 mg for 3 successive days. A single antibody injection was repeated after 7 days. For short-term depletion of T-cell subsets, immunocompetent mice as well as adoptive lymphocyte transfer recipients were injected intraperitoneally with 1 mg of anti-CD4 or anti-CD8 MAb every fourth day, starting 1 h after infection and cell transfer. For in vivo neutralization of IFN--y, mice were injected with 1 mg of R4.6A2 MAb in 0.5 ml of PBS for 2 successive days starting from the day of infection. Every third day, another single injection of 1 mg of anti-IFN--y antibody was carried out. Experiments were terminated after 2 weeks.
The in vivo activity of rIFN--y was tested by injecting mice with a single dose of 2 x 104 U of rIFN-y intraperitoneally every other day for the test period of 2 weeks. Control mice received PBS.
The prophylactic adoptive cell transfer was performed as described previously (27) . In brief, recipient mice were immunodepleted by total-body gamma irradiation, with Detection of specific antibodies. The enzyme-linked immunosorbent assay (ELISA) for quantitating MCMV-specific antibodies and the plaque reduction assay for determination of titers of virus-neutralizing antibodies have been described previously (10) . The antibody response of mice to rat IgG, after treatment with rat MAb in vivo, was monitored by ELISA with purified rat IgG as the antigen.
RESULTS
CD4 subset required for virus clearance from salivary gland tissues. The importance of the CD4 T-lymphocyte subset in clearance of CMV infection and establishment of latency was shown previously for the BALB/c (H-2d) strain of mice (11) . This mouse strain is highly susceptible to MCMV disease, whereas other strains, such as CBA (H-2k), are significantly more resistant (23) . We therefore asked whether the requirement for CD4 lymphocytes for virus clearance characterizes only the susceptible BALB/c strain or represents a general mechanism. Immunocompetent and CD4 subset-depleted mice of both strains were infected with 2 x 105 PFU of MCMV, and the kinetics of virus clearance in the salivary gland, the organ which is cleared last during CMV infection, was studied. As shown in Fig. 1 (19) . Thl cells are characterized by the production of interleukin-2 (IL-2), IFN-y, and lymphotoxin (20) . We had observed that the protective effect of CD4+ T lymphocytes requires the cooperation of the CD4 subset with other cells, which to us appeared indicative of cytokine involvement (12) . To test the contribution of endogenously produced IFN--y, mice were treated with anti-IFN-y antibody R4.6A2
to neutralize the endogenous activity of IFN--y. The effect of anti-IFN--y treatment was compared with the known effect of anti-CD4 and anti-CD8 antibody treatment (Fig. 2) . Neutralization of IFN-y abolished virus clearance from the salivary gland to a degree similar to that resulting from CD4 subset depletion, whereas elimination of the CD8 subset had no VOL. 66, 1992 effect. These results suggest that Thl cells releasing IFN-y have a central role in T-lymphocyte-mediated MCMV clearance from salivary gland tissues.
IFN--y neutralization does not prevent induction of the antiviral immune response. Cytokines have complex effects, and neutralization of IFN--y could either block the generation of the specific immune response to MCMV or inhibit the effector phase. We first studied the effect of IFN--y neutralization on generation of the protective T-lymphocyte response. Spleen cells from MCMV-infected and anti-IFN--ytreated BALB/c mice and spleen cells from control mice receiving isotype-matched irrelevant antibody were tested for their capacity to limit virus spread after adoptive transfer into MCMV-infected and gamma-irradiated syngeneic recipients. The irradiation protocol of 6 Gy is equivalent to the lethal dose of 50% of the mice within 30 days and abolishes the capacity of recipient mice to mount a specific immune response during the test period (15, 27) . Two weeks later, recipients were killed, and virus titers in their organs were determined (Fig. 3) . Unlike cells from nonprimed cell donors (Fig. 3A) , the same number of cells (106) from MCMVprimed mice showed a strong antiviral effect ( Fig. 3B and C) , which is the function of CD8+ T lymphocytes. The degree of virus titer reduction was comparable between recipients of cells from MCMV-primed donors treated with anti-IFN--y and recipients of cells from donors receiving only control antibody. Therefore, neutralization of IFN--y did not apparently interfere with the maturation of antiviral effector cells.
To study the potential effect of IFN--y on the production of antiviral antibodies, sera derived from anti-IFN-y-treated mice and from control animals were analyzed for virusspecific antibodies. Titers were determined by an ELISA and by virus neutralization. No significant difference between these two groups of mice was seen, which indicated that IFN--y neutralization is without effect on the magnitude and biological activity of the MCMV-specific antibody response (Table 1) .
IFN--y required for CD4+ but not for CD8+ T-lymphocyte effector functions. In the absence of a major effect of IFN--y neutralization during the induction phase of the specific immune response, we studied whether IFN--y neutralization did interfere with antiviral T-lymphocyte effector functions in vivo. This function of T lymphocytes was again tested in an adoptive cell transfer system. Unlike in the experiment described above, not only donors but also cell recipients were treated. MCMV-primed cell donors were either fully 4 (Fig.  4) , demonstrating again that it is mainly the CD4 T-lymphocyte subset which contributes to virus clearance in this organ. In line with this fact was that treatment with anti-CD4 abolished the protective activity of both donor cell populations. Treatment of recipients with anti-IFN--y had an effect comparable to that of anti-CD4 injection. Although not significant in this experiment, nevertheless, it was an invariable observation in several similar experiments that, after anti-CD4 treatment, the resulting virus titer was even higher than after anti-IFN-y administration, indicating that anti-IFN-y significantly but perhaps not completely eliminated the antiviral activity of the CD4 subset. Together, these data show that IFN-y is required mainly during the effector phase and that it is crucial for the clearance of MCMV infection by the primed Thl subset of CD4+ T lymphocytes.
The situation was different when virus titers were studied in those tissues in which mainly CD8+ T lymphocytes limit MCMV replication (Fig. 5) . In the lungs and the spleen, elimination of the CD4 subset, as expected from the results of previous studies (11, 12) , did not abolish the control of virus spread. Although there was some effect of CD4 depletion on virus titers in the lungs, only elimination of the CD8 subset abolished the protective activity. Treatment of recipients with antibodies to IFN--y had an effect similar to the removal of the CD4 T-lymphocyte subset. Therefore, unlike the effector function of the CD4 subset in the salivary gland, the activity of the CD8 subset operative in other tissues is not dependent upon endogenous IFN--y activity.
rIFN-y cannot replace the antiviral CD4 subset functions in vivo. CD4 T-lymphocyte-depleted mice develop a chronic productive infection of the salivary gland, whereas CD8 T-lymphocyte-depleted animals clear this tissue (12) . Since anti-IFN--y administration abolished the function of the CD4 subset in the salivary glands, we asked whether IFN--y is the main effector molecule and whether it can replace the CD4 T-lymphocyte function in the salivary glands. Three experimental protocols were carried out (Table 2) . First, infection and administration of rIFN--y were initiated simultaneously in irradiated mice. Second, mice were depleted only for the CD4 subset, infected, and injected with rIFN--y. Third, mice were depleted for the CD4 subset and infected, but rIFN-y injection was delayed until 2 weeks after the infection. In all three groups, rIFN-,y treatment was continued for 2 weeks, and the effect on virus titers in the salivary gland was tested. In none of the experiments was a therapeutic effect of rIFN--y administration detectable. This was concluded from the observation that in irradiated mice, the virus titers of saline-and rIFN--y-injected mice were comparable (group A). rIFN--y could not diminish or prevent the effect of CD4 subset removal (groups B and C). rIFN--y injection, however, was not without any biological activity in vivo, since the lymphocytes reconstituting the thymus after irradiation that were obtained from mice treated according to the first protocol showed enhanced MHC class I antigen expression (Fig. 6 ). Considering that a similar dose of rIFN--y proved to be efficacious during bacterial (14, 29) , parasitic (28) , and viral (15) infection, we concluded that IFN-y alone cannot substitute for the function of the CD4 subset.
Weak antiviral effect of rIFN-y in vitro. The results described above predicted that rIFN--y should not have a strong direct antiviral effect. This question was addressed by a plaque reduction assay (Fig. 7) . Permissive murine embryo fibroblasts were incubated with different concentrations of rIFN-y prior to infection with MCMV, and rIFN--y was also maintained in the medium throughout the test period. Plaques were counted 96 h following infection. There was only a minimal effect of rIFN--y on plaque numbers at physiological concentrations of the cytokine, indicating that the capacity of IFN--y to induce an antiviral state in fibroblasts is low. Only at a concentration of 100 U of IFN--y and higher was the number of MCMV plaques decreased significantly.
DISCUSSION
Limitation of acute infection and establishment of viral latency are the hallmarks of an efficient host immune surveillance during a herpesvirus infection. NK cells are active during the first days of infection (33) , and the control of acute MCMV disease is an essential function of CD8+ T lymphocytes (27) , whereas final clearance of productive infection and establishment of latency in the salivary gland require CD4+ T lymphocytes. In the absence of clearance, a persistent state of viral infection is established (11) . The spread to other tissues is under control of the CD8 subset, and antibodies probably also contribute. Thus, CD4+ T lymphocytes have a pivotal role in establishment of MCMV latency and the prevention of horizontal transmission. Consequently, it is necessary to evaluate their physiological role in vivo. Here we report three major findings. First, the antiviral activity of the CD4+ T lymphocytes is a function of the Thl subset; second, the protective effector function of CD4+ but not of CD8+ T lymphocytes is associated with the release of the cytokine IFN-y; and third, the role of IFN-y in the (11, 12 (25) . Altogether, the experimental evidence suggested that the neutralization of endogenous IFN--y should mainly affect the effector phase. Proof 
